Millennium Management Llc Purchases 6,175 Shares of Sensei Biotherapeutics (NASDAQ:SNSE) Stock

Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) major shareholder Millennium Management Llc purchased 6,175 shares of the firm’s stock in a transaction dated Wednesday, April 1st. The stock was acquired at an average price of $34.49 per share, with a total value of $212,975.75. Following the purchase, the insider directly owned 147,731 shares of the company’s stock, valued at approximately $5,095,242.19. The trade was a 4.36% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Large shareholders that own 10% or more of a company’s shares are required to disclose their sales and purchases with the SEC.

Millennium Management Llc also recently made the following trade(s):

• On Thursday, March 26th, Millennium Management Llc sold 1,857 shares of Sensei Biotherapeutics stock. The stock was sold at an average price of $28.12, for a total value of $52,218.84.
• On Friday, March 27th, Millennium Management Llc sold 505 shares of Sensei Biotherapeutics stock. The stock was sold at an average price of $26.81, for a total value of $13,539.05.
• On Monday, March 30th, Millennium Management Llc sold 888 shares of Sensei Biotherapeutics stock. The stock was sold at an average price of $26.61, for a total value of $23,629.68.
• On Monday, March 30th, Millennium Management Llc acquired 9,533 shares of Sensei Biotherapeutics stock. The stock was purchased at an average cost of $25.86 per share, with a total value of $246,523.38.
• On Friday, March 27th, Millennium Management Llc acquired 15,321 shares of Sensei Biotherapeutics stock. The stock was purchased at an average cost of $26.61 per share, with a total value of $407,691.81.
• On Thursday, March 26th, Millennium Management Llc acquired 5,731 shares of Sensei Biotherapeutics stock. The stock was purchased at an average cost of $28.62 per share, with a total value of $164,021.22.
• On Tuesday, March 31st, Millennium Management Llc sold 1,591 shares of Sensei Biotherapeutics stock. The stock was sold at an average price of $25.49, for a total value of $40,554.59.
• On Wednesday, April 1st, Millennium Management Llc sold 1,150 shares of Sensei Biotherapeutics stock. The stock was sold at an average price of $31.65, for a total value of $36,397.50.
• On Tuesday, March 31st, Millennium Management Llc acquired 6,005 shares of Sensei Biotherapeutics stock. The stock was purchased at an average cost of $28.16 per share, with a total value of $169,100.80.
• On Thursday, April 2nd, Millennium Management Llc sold 7,666 shares of Sensei Biotherapeutics stock. The stock was sold at an average price of $32.12, for a total value of $246,231.92.

Sensei Biotherapeutics Price Performance

Shares of SNSE traded up $0.61 during trading hours on Friday, hitting $20.43. The stock had a trading volume of 40,084 shares, compared to its average volume of 223,112. Sensei Biotherapeutics, Inc. has a 12 month low of $5.25 and a 12 month high of $36.76. The firm has a market capitalization of $27.40 million, a PE ratio of -1.23 and a beta of -0.18. The stock has a fifty day moving average price of $29.11 and a 200 day moving average price of $17.85.

Sensei Biotherapeutics (NASDAQ:SNSE) last issued its quarterly earnings data on Friday, May 15th. The company reported ($131.45) EPS for the quarter, missing the consensus estimate of ($0.62) by ($130.83). As a group, analysts anticipate that Sensei Biotherapeutics, Inc. will post -2.77 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms have issued reports on SNSE. Leerink Partners began coverage on Sensei Biotherapeutics in a report on Monday, April 20th. They set an “outperform” rating and a $50.00 price target for the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Sensei Biotherapeutics in a report on Friday, April 24th. Finally, Zacks Research raised Sensei Biotherapeutics to a “hold” rating in a report on Tuesday, April 21st. One research analyst has rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $40.00.

Key Sensei Biotherapeutics News

Here are the key news stories impacting Sensei Biotherapeutics this week:

• Positive Sentiment: Sensei Biotherapeutics reported first-quarter 2026 results and said the quarter was “transformational,” highlighting the acquisition of Faeth Therapeutics and a concurrent $200 million private placement backed by leading life sciences investors, which may strengthen the balance sheet and support the company’s strategy. Sensei Biotherapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
• Neutral Sentiment: The company also disclosed that major shareholder Millennium Management made several purchases in late March and early April, which can signal insider confidence, although the filing also showed some offsetting sales in the same period. SEC insider filing
• Negative Sentiment: The earnings release showed a very large quarterly loss, with reported EPS of ($131.45) versus expectations of ($0.62), underscoring continued financial volatility and likely limiting enthusiasm for the stock. Quarterly earnings press release

Hedge Funds Weigh In On Sensei Biotherapeutics

An institutional investor recently raised its position in Sensei Biotherapeutics stock. Renaissance Technologies LLC lifted its holdings in Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) by 10.6% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 11,516 shares of the company’s stock after acquiring an additional 1,100 shares during the period. Renaissance Technologies LLC owned 0.91% of Sensei Biotherapeutics worth $123,000 at the end of the most recent reporting period. 10.50% of the stock is currently owned by institutional investors.

Sensei Biotherapeutics Company Profile

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of immunotherapies that harness both the innate and adaptive arms of the immune system to treat cancer and autoimmune diseases. Utilizing proprietary antibody engineering and biologics platforms, Sensei aims to develop next-generation checkpoint modulators and immune agonists designed to overcome the limitations of current therapies.

The company’s lead programs include SIS-100, a first-in-class antagonist targeting Siglec-15 being evaluated in solid tumors to relieve immune suppression in the tumor microenvironment, and SIS-101, an antibody directed against CD39 intended to restore T-cell function by modulating adenosine signaling pathways.